Bristol-Myers Squibb Co. will make some big changes to its research and development leadership after it merges with Celgene Corp.. The company announced its new post-merger research and commercial leadership teams on 5 June, with an outsider taking over the top R&D spot.
Novartis AG's head of oncology development Samit Hirawat will join the company as chief medical officer-global drug development, leading drug development across therapeutic areas. He will be responsible for overseeing the pipeline from proof-of-concept through commercialization
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
